Drugs / Trifluridine/tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02743221 | Apr 2016 → Jan 2018 | colorectal cancer | Servier | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743221 ↗ |
| Route | Oral | “Trifluridine/tipiracil was administered at 35 mg/m2/dose orally” NCT02743221 ↗ |